Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 12/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.46 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 15/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6488840 | 1.00 | NOS2 (0.46) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6498942 | 0.92 | NOS2 (0.51) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6490771 | 0.86 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6490777 | 0.86 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6492120 | 0.77 | NOS2 (0.49) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6501101 | 0.77 | NOS2 (0.63) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6504713 | 0.76 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6504718 | 0.76 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6492576 | 0.75 | NOS2 (0.39) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6492563 | 0.75 | NOS2 (0.39) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1263711-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | SLC6A2 1776/4885SLC6A4 2468/4885KCNH2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.